Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | STS | P08842 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15732481 | 0.86 | NOTUM (0.50) | EPHX2TAS1R3TAS1R1TAS1R2CYP2C19 | |
| SCHEMBL2063004 | 0.85 | EPHX2 (0.57) | EPHX2GPR119KMT2ASTS | |
| SCHEMBL22305299 | 0.78 | TAS1R3 (0.44) | TAS1R3TAS1R1TAS1R2POLB | |
| SCHEMBL15732637 | 0.78 | NOTUM (0.45) | EPHX2TAS1R3TAS1R1TAS1R2NOTUM | |
| SCHEMBL311398 | 0.78 | EPHX2 (0.57) | EPHX2GPR119KMT2ASTS | |
| SCHEMBL11904707 | 0.73 | STS (0.50) | EPHX2GPR119KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL311110 | 0.72 | EPHX2 (0.39) | EPHX2NOTUMGPR119KMT2AMEN1 | |
| SCHEMBL4305734 | 0.71 | LMNA (0.43) | TAS1R3TAS1R1TAS1R2POLB | |
| SCHEMBL312673 | 0.71 | EPHX2 (0.49) | EPHX2GPR119KMT2AMEN1STS | |
| SCHEMBL17438906 | 0.71 | PREP (0.42) | EPHX2TAS1R3TAS1R1TAS1R2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2148880-B1 | P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2014-05-28 | — | — | EP | disclosed |
| US-8334293-B2 | P70 S6 kinase inhibitor and EGFR inhibitor combination therapy | ELI LILLY AND COMPANY (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-03-22 | — | — | US | disclosed |
| US-8093383-B2 | P70 S6 kinase inhibitors | ELI LILLY AND COMPANY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20110212977-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110207752-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| EP-2355821-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | Eli Lilly and Company (US) | 2011-08-17 | — | — | EP | disclosed |
| EP-2355820-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | Eli Lilly and Company (US) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010056574-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| WO-2010056575-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | ELI LILLY AND COMPANY (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-2148880-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2010-02-03 | — | — | EP | disclosed |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY | 2009-06-25 | — | — | US | disclosed |
| WO-2008140947-A1 | P70 S6 KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212977-A1 | P70 S6 KINASE INHIBITOR AND MTOR INHIBITOR COMBINATION THERAPY | MTOR, RPS6KA1, RPS6KA4 | EPHX2 4881/4885TAS1R3 3840/4885TAS1R1 3928/4885 |
| US-20090163714-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | EPHX2 4803/4885TAS1R3 4642/4885TAS1R1 4458/4885 |
| US-20110207752-A1 | P70 S6 KINASE INHIBITOR AND EGFR INHIBITOR COMBINATION THERAPY | RPS6KA1, RPS6KA3, RPS6KA4 | EPHX2 4781/4885TAS1R3 3682/4885TAS1R1 3752/4885 |
| US-20120071490-A1 | P70 S6 KINASE INHIBITORS | RPS6KA6, RPS6KA1, RPS6KA2 | EPHX2 4803/4885TAS1R3 4642/4885TAS1R1 4458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.